AB ABBV AbbVie Inc. Loading... : Bullish and Bearish Analyst Opinions

European Commission approves AbbVie's Aquipta for acute treatment of migraine in adults, expanding the drug's market access.

The author notes insider buying in biotech and healthcare plays, aligning with a defensive rotation thesis, but does not state a personal position.

Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis, including a biologic-refractory trial no pharma giant has run, could drive over $5B in peak sales and make NKTR a glaring M&A candidate at current prices.

Adam May agrees with another user that AbbVie is developing a bispecific antibody, but provides no forward-looking price or trade view.

ABBV cited as having competitive advantage in extended half-life bispecific and IL23 antibodies compared to SYRE/ORKA; no directional trade stance from speaker.

"Healthcare" allocation at 7%. Non-tech exposure for stability and dividend income. Defensive sector allocation to reduce portfolio volatility. Patent cliffs, drug pricing pressures, pipeline setbacks.

Go short AbbVie due to the new competitive threat from J&J's psoriasis pill, which could erode the market share of its key drug, Skyrizi.

Cramer notes that February "demolished software" and "minimized hardware" but the winners were "prosaic companies with popular brands" and "earthmovers." In a month of indecision, inflation, and rate fears, capital is fleeing high-beta tech and hiding in tangible, defensive value stocks and industrials. LONG. These are the current safe havens in a volatile market. A sudden return to "risk-on" sentiment could see these lag behind tech.

February winners were "prosaic companies" with popular brands and earth movers. In a month where software and hardware were demolished, capital hid in these defensive names. This trend is the current market regime. Winners/Holds. Rotation back into risk-on tech.

Rep. Burlison discusses the "Khloe Cole Act," which the DOJ helped draft, creating a "private right of action" (ability to sue) for patients to sue doctors and pharma companies for gender-affirming care (puberty blockers/surgeries) with a lengthy statute of limitations. Bondi expresses strong support ("proud to work hand in hand"). This legislation opens a new floodgate of medical malpractice and product liability litigation against hospitals and pharmaceutical companies involved in these treatments. Similar to the opioid crisis, creating a specific legal framework for mass torts against healthcare providers creates unquantifiable liability overhangs for specific hospital chains and drug manufacturers. The legislation may not pass Congress; the number of claimants may be statistically insignificant to large cap pharma earnings.